Cambridge, Massachusetts-based Biogen Inc. (BIIB) operates as a leading biotech firm, pioneering innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and communities. Valued at $26.6 billion by market cap, it has a deep understanding of human biology and leverages different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Companies worth$10 billion or more are generally described as "large-cap stocks." Bi ...